Malignant melanoma with BRAF‐V600 mutation, either targeted therapy after immunotherapy as recommended by NCCN guidelines, or immunization before targeted19 as recommended by DREAMseq studies, suggests that BRAF‐V600 mutant metastatic melanoma could benefit from immunotherapy. This evidence concerns the gene BRAF and melanoma.